{"title":"PON1、APOE和SDF-1基因多态性与视网膜静脉闭塞患者玻璃体内抗vegf治疗反应的关系","authors":"Antonios Ragkousis, Dimitrios Kazantzis, Ilias Georgalas, Panagiotis Theodossiadis, Christos Kroupis, Irini Chatziralli","doi":"10.1080/08820538.2023.2283028","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to determine whether specific genetic polymorphisms affect the response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with macular oedema secondary to retinal vein occlusion (RVO).</p><p><strong>Methods: </strong>Participants in this prospective study were 50 patients with macular oedema secondary to RVO, who were treated with intravitreal ranibizumab or aflibercept, and were followed-up for 12 months after initiation of treatment. Five single nucleotide polymorphisms (SNPs) from three different genes (<i>APOE</i>, <i>PON1</i>, <i>SDF-1</i>) were examined as potential predictors for treatment response to intravitreal anti-VEGF agents.</p><p><strong>Results: </strong>Patients with the LL genotype of the <i>PON1</i> L55M SNP had significantly higher reduction in central subfield thickness (CST) at month 12 after initiation of intravitreal anti-VEGF treatment (101.63 ± 56.80 μm in LL vs. 72.44 ± 39.41 μm in LM vs. 40.25 ± 19.33 μm in MM, <i>p</i> = .026). Patients with the M allele of the <i>PON1</i> L55M SNP were significantly associated with lower reduction in CST compared to non-carriers (68.29 ± 38.77 μm in LM + MM vs. 101.63 ± 56.80 μm in LL, <i>p</i> = .032).</p><p><strong>Conclusion: </strong><i>PON1</i> L55M SNP may serve as a promising genetic biomarker for predicting response to intravitreal anti-VEGF treatment in patients with macular oedema due to RVO.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of <i>PON1</i>, <i>APOE</i> and <i>SDF-1</i> Gene Polymorphisms with Treatment Response to Intravitreal Anti-VEGF Treatment in Patients with Retinal Vein Occlusion.\",\"authors\":\"Antonios Ragkousis, Dimitrios Kazantzis, Ilias Georgalas, Panagiotis Theodossiadis, Christos Kroupis, Irini Chatziralli\",\"doi\":\"10.1080/08820538.2023.2283028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The purpose of this study was to determine whether specific genetic polymorphisms affect the response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with macular oedema secondary to retinal vein occlusion (RVO).</p><p><strong>Methods: </strong>Participants in this prospective study were 50 patients with macular oedema secondary to RVO, who were treated with intravitreal ranibizumab or aflibercept, and were followed-up for 12 months after initiation of treatment. Five single nucleotide polymorphisms (SNPs) from three different genes (<i>APOE</i>, <i>PON1</i>, <i>SDF-1</i>) were examined as potential predictors for treatment response to intravitreal anti-VEGF agents.</p><p><strong>Results: </strong>Patients with the LL genotype of the <i>PON1</i> L55M SNP had significantly higher reduction in central subfield thickness (CST) at month 12 after initiation of intravitreal anti-VEGF treatment (101.63 ± 56.80 μm in LL vs. 72.44 ± 39.41 μm in LM vs. 40.25 ± 19.33 μm in MM, <i>p</i> = .026). Patients with the M allele of the <i>PON1</i> L55M SNP were significantly associated with lower reduction in CST compared to non-carriers (68.29 ± 38.77 μm in LM + MM vs. 101.63 ± 56.80 μm in LL, <i>p</i> = .032).</p><p><strong>Conclusion: </strong><i>PON1</i> L55M SNP may serve as a promising genetic biomarker for predicting response to intravitreal anti-VEGF treatment in patients with macular oedema due to RVO.</p>\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/08820538.2023.2283028\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820538.2023.2283028","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究的目的是确定特异性遗传多态性是否影响视网膜静脉闭塞(RVO)继发性黄斑水肿患者对玻璃体内抗血管内皮生长因子(anti-VEGF)治疗的反应。方法:这项前瞻性研究的参与者是50例继发于RVO的黄斑水肿患者，他们接受了玻璃体内雷尼单抗或阿非利塞普治疗，并在开始治疗后随访了12个月。来自三个不同基因(APOE, PON1, SDF-1)的五个单核苷酸多态性(snp)被检测为玻璃体内抗vegf药物治疗反应的潜在预测因子。结果:PON1 L55M SNP的LL基因型患者在开始玻璃体内抗vegf治疗后12个月的中心亚场厚度(CST)降低率显著高于LL(101.63±56.80 μm)， LM(72.44±39.41 μm)， MM(40.25±19.33 μm)， p = 0.026。与非携带者相比，携带PON1 L55M SNP M等位基因的患者CST降低显著相关(LM + MM为68.29±38.77 μm, LL为101.63±56.80 μm, p = 0.032)。结论:PON1 L55M SNP可能作为预测RVO黄斑水肿患者玻璃体内抗vegf治疗反应的有希望的遗传生物标志物。
Association of PON1, APOE and SDF-1 Gene Polymorphisms with Treatment Response to Intravitreal Anti-VEGF Treatment in Patients with Retinal Vein Occlusion.
Purpose: The purpose of this study was to determine whether specific genetic polymorphisms affect the response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with macular oedema secondary to retinal vein occlusion (RVO).
Methods: Participants in this prospective study were 50 patients with macular oedema secondary to RVO, who were treated with intravitreal ranibizumab or aflibercept, and were followed-up for 12 months after initiation of treatment. Five single nucleotide polymorphisms (SNPs) from three different genes (APOE, PON1, SDF-1) were examined as potential predictors for treatment response to intravitreal anti-VEGF agents.
Results: Patients with the LL genotype of the PON1 L55M SNP had significantly higher reduction in central subfield thickness (CST) at month 12 after initiation of intravitreal anti-VEGF treatment (101.63 ± 56.80 μm in LL vs. 72.44 ± 39.41 μm in LM vs. 40.25 ± 19.33 μm in MM, p = .026). Patients with the M allele of the PON1 L55M SNP were significantly associated with lower reduction in CST compared to non-carriers (68.29 ± 38.77 μm in LM + MM vs. 101.63 ± 56.80 μm in LL, p = .032).
Conclusion: PON1 L55M SNP may serve as a promising genetic biomarker for predicting response to intravitreal anti-VEGF treatment in patients with macular oedema due to RVO.
期刊介绍：
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
